Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel 'soft' beta-blockers as potential safe antiglaucoma agents.

N Bodor1, A elKoussi

  • 1University of Florida, College of Pharmacy, J. Hillis Miller Health Center, Gainesville 32610.

Current Eye Research
|April 1, 1988
PubMed
Summary

New "soft" beta-blockers were developed to treat glaucoma. The best candidate, ester 2, effectively lowers intraocular pressure (IOP) long-term without systemic side effects, offering a promising glaucoma treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recent advances in the design and development of soft drugs.

Die Pharmazie·2014
Same author

Soft Drugs VI. The Application of the Inactive Metabolite Approach for Design of Soft β-Blockers1?2.

Pharmaceutical research·2013
Same author

Improved Delivery Through Biological Membranes. XVII. A Site-Specific Chemical Delivery System as a Short-Acting Mydriatic Agent.

Pharmaceutical research·2013
Same author

Improved Delivery Through Biological Membranes. XXIV. Synthesis, in Vitro Studies, and in Vivo Characterization of Brain-Specific and Sustained Progestin Delivery Systems.

Pharmaceutical research·2013
Same author

The effects of delta1-cortienic acid on skin blanching, pharmacokinetics and stability of loteprednol etabonate.

Die Pharmazie·2012
Same author

Brain-targeted delivery of estrogens.

Reviews in the neurosciences·2011

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Glaucoma treatment requires effective intraocular pressure (IOP) reduction.
  • Systemic side effects of traditional beta-blockers limit their use.
  • The inactive metabolite approach offers a strategy to develop targeted ocular therapies.

Purpose of the Study:

  • To design and synthesize novel "soft" beta-blockers using the inactive metabolite approach.
  • To evaluate the efficacy and safety of these compounds for reducing IOP in rabbits.
  • To identify a potential antiglaucoma agent with improved pharmacokinetic and pharmacodynamic properties.

Main Methods:

  • Synthesis of lipophilic esters derived from metoprolol's acidic metabolite.
  • Testing of novel compounds on rabbit eyes to measure IOP reduction.

Related Experiment Videos

  • Assessment of hydrolysis rates in human blood to determine systemic exposure.
  • Evaluation of local ocular irritation and unilateral treatment effects.

    • Main Results:

    • Most synthesized compounds showed superior and prolonged ocular hypotensive activity compared to Esmolol.
    • Adamantaneethyl ester 2 demonstrated significant, long-lasting IOP reduction without ocular irritation.
    • Ester 2 rapidly hydrolyzed in human blood (t1/2 = 7.0 min) to an inactive metabolite.
    • Unilateral treatment with ester 2 resulted in localized IOP reduction, confirming targeted action.

    Conclusions:

    • Adamantaneethyl ester 2 is a promising candidate for an antiglaucoma agent.
    • The "soft" beta-blocker design effectively separates ocular activity from systemic effects.
    • This approach minimizes systemic beta-blockade, enhancing safety for glaucoma patients.